Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | RAB9A, member RAS oncogene family | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus granulosus | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus multilocularis | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | ras-related protein Rab-5B | RAB9A, member RAS oncogene family | 201 aa | 165 aa | 30.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | phosphoglycerate kinase, putative | 0.0198 | 0.0838 | 0.0838 |
Echinococcus granulosus | vesicular acetylcholine transporter | 0.0941 | 0.581 | 1 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.1568 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1568 | 1 | 1 |
Leishmania major | phosphoglycerate kinase B, cytosolic | 0.0198 | 0.0838 | 0.0838 |
Toxoplasma gondii | phosphoglycerate kinase PGKI | 0.0198 | 0.0838 | 0.5 |
Toxoplasma gondii | phosphoglycerate kinase PGKII | 0.0198 | 0.0838 | 0.5 |
Brugia malayi | vesicular acetylcholine transporter unc-17 | 0.0941 | 0.581 | 0.581 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.1424 | 0.064 |
Trichomonas vaginalis | phosphoglycerate kinase, putative | 0.0198 | 0.0838 | 0.5 |
Echinococcus multilocularis | vesicular acetylcholine transporter | 0.0941 | 0.581 | 1 |
Trichomonas vaginalis | phosphoglycerate kinase, putative | 0.0198 | 0.0838 | 0.5 |
Entamoeba histolytica | phosphoglycerate kinase, putative | 0.0198 | 0.0838 | 0.5 |
Mycobacterium leprae | Probable phosphoglycerate kinase Pgk | 0.0198 | 0.0838 | 0.5 |
Treponema pallidum | phosphoglycerate kinase | 0.0198 | 0.0838 | 0.5 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.1424 | 0.1179 |
Brugia malayi | hypothetical protein | 0.0286 | 0.1424 | 0.1424 |
Plasmodium falciparum | phosphoglycerate kinase | 0.0198 | 0.0838 | 0.5 |
Giardia lamblia | Phosphoglycerate kinase | 0.0198 | 0.0838 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0801 | 0.4874 | 0.4405 |
Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.0941 | 0.581 | 0.5 |
Leishmania major | phosphoglycerate kinase C, glycosomal | 0.0198 | 0.0838 | 0.0838 |
Brugia malayi | Phosphoglycerate kinase | 0.0198 | 0.0838 | 0.0838 |
Trypanosoma brucei | phosphoglycerate kinase | 0.0198 | 0.0838 | 0.0838 |
Schistosoma mansoni | vesicular acetylcholine transporter | 0.0941 | 0.581 | 1 |
Mycobacterium ulcerans | phosphoglycerate kinase | 0.0198 | 0.0838 | 0.5 |
Trypanosoma cruzi | phosphoglycerate kinase, putative | 0.0198 | 0.0838 | 0.0838 |
Leishmania major | C-8 sterol isomerase-like protein | 0.1568 | 1 | 1 |
Mycobacterium tuberculosis | Probable phosphoglycerate kinase Pgk | 0.0198 | 0.0838 | 0.5 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.1568 | 1 | 1 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.1424 | 0.1179 |
Wolbachia endosymbiont of Brugia malayi | phosphoglycerate kinase | 0.0198 | 0.0838 | 0.5 |
Chlamydia trachomatis | phosphoglycerate kinase | 0.0198 | 0.0838 | 0.5 |
Trypanosoma brucei | phosphoglycerate kinase | 0.0198 | 0.0838 | 0.0838 |
Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.0941 | 0.581 | 0.5427 |
Plasmodium vivax | phosphoglycerate kinase, putative | 0.0198 | 0.0838 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for Rab9 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 20.5878 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493106, AID493143] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 63.0957 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.